IP strenghtening for MIDRIX, a unique manufacturing process for dendritic cell immunotherapy in solid cancers (MIDRIX)

The preclinical development of a unique dendritic cell vaccine against lung cancer has been completed. This cellular immunotherapy is aimed at a growing unmet need in this patient population. A spin-off is being developed to raise the required capital in order to continue a successful phase Ia study to a phase Ib and phase II study. A number of experiments are planned to strengthen the patent position.